| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| C655923-1ml | 1ml | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $440.90 |
| Specifications & Purity | 10mM in DMSO |
|---|---|
| Biochemical and Physiological Mechanisms | Cl-NQTrp signifcantly disrupts the preformed fbrillar aggregates of Tau-derived PHF6 (VQIVYK) peptide and full-length tau protein. |
| Storage Temp | Store at -80°C |
| Shipped In | Ice chest + Ice pads |
| Product Description | Cl-NQTrp signifcantly disrupts the preformed fbrillar aggregates of Tau-derived PHF6 (VQIVYK) peptide and full-length tau protein. In Vitro Cl-NQTrp efciently disassembled pre-formed PHF6 peptide fbrils. Cl-NQTrp has the potential to induce conformational changes in PHF6 peptide oligomers. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Cl-NQTrp could be a unique potential therapeutic for AD since it targets aggregation of both Aβ and tau. Cl-NQTrp significantly alleviates the shorter life span of htau-expressing flies, leading to 58% viability on day 29. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Virgin females, carrying either the eye GMR -Gal4 driver or the pan-neuronal driver elav c155 -Gal4 on chromosome X, were collected and crossed with males carrying UAS-h tau on the 2nd chromosome or with wild-type Oregon-R (OR) males as a control. Dosage: 0.75 mg/mL. Administration: Dripped every other day. Result: Inhibited PHF6 aggregation and ameliorates eye neurodegeneration Drosophila overexpressing the human tau protein (htau). |
| Canonical SMILES | ClC(C(C1=C(C=CC=C1)C2=O)=O)=C2N[C@H](C(O)=O)CC3=CNC4=C3C=CC=C4 |
|---|---|
| Molecular Weight | 394.81 |
Starting at $400.90
